119 related articles for article (PubMed ID: 9713278)
1. Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in southeastern Netherlands, 1971-1995.
Post PN; Kil PJ; Crommelin MA; Schapers RF; Coebergh JW
Eur J Cancer; 1998 Apr; 34(5):705-9. PubMed ID: 9713278
[TBL] [Abstract][Full Text] [Related]
2. Trends in survival of prostate cancer in southeastern Netherlands, 1971-1989.
Post PN; Kil PJ; Coebergh JW
Int J Cancer; 1999 May; 81(4):551-4. PubMed ID: 10225443
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
4. Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: data from the Rotterdam Cancer Registry.
Spapen SJ; Damhuis RA; Kirkels WJ
BJU Int; 2000 Mar; 85(4):474-80. PubMed ID: 10691827
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer and prostate-specific antigen testing in New South Wales.
Smith DP; Supramaniam R; Marshall VR; Armstrong BK
Med J Aust; 2008 Sep; 189(6):315-8. PubMed ID: 18803534
[TBL] [Abstract][Full Text] [Related]
6. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?
Winter A; Sirri E; Jansen L; Wawroschek F; Kieschke J; Castro FA; Krilaviciute A; Holleczek B; Emrich K; Waldmann A; Brenner H;
BJU Int; 2017 Apr; 119(4):550-559. PubMed ID: 27208546
[TBL] [Abstract][Full Text] [Related]
8. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
Collin SM; Martin RM; Metcalfe C; Gunnell D; Albertsen PC; Neal D; Hamdy F; Stephens P; Lane JA; Moore R; Donovan J
Lancet Oncol; 2008 May; 9(5):445-52. PubMed ID: 18424233
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
10. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Tonita JM; Skarsgard D; Muhajarine N
Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
[TBL] [Abstract][Full Text] [Related]
11. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of fatal prostate cancer may explain the rise in mortality in The Netherlands.
Post PN; Straatman H; Kiemeney LA; Coebergh JW
Int J Epidemiol; 1999 Jun; 28(3):403-8. PubMed ID: 10405841
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival of prostate cancer in southeastern Netherlands.
Post PN; Hendrikx AJ; Hansen BE; van der Heijden LH; Coebergh JW
Acta Oncol; 2000; 39(1):101-4. PubMed ID: 10752662
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening in the Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
[TBL] [Abstract][Full Text] [Related]
15. Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia.
Coory MD; Baade PD
Med J Aust; 2005 Feb; 182(3):112-5. PubMed ID: 15698354
[TBL] [Abstract][Full Text] [Related]
16. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
[TBL] [Abstract][Full Text] [Related]
17. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
18. Trends in prostate cancer incidence and mortality before and after the introduction of PSA testing in the Slovak and Czech Republics.
Ondrusova M; Ondrus D; Karabinos J; Muzik J; Kliment J; Gulis G
Tumori; 2011; 97(2):149-55. PubMed ID: 21617707
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer in Saskatchewan Canada, before and during the PSA era.
Skarsgard D; Tonita J
Cancer Causes Control; 2000 Jan; 11(1):79-88. PubMed ID: 10680732
[TBL] [Abstract][Full Text] [Related]
20. Decrease in prostate cancer incidence and mortality in Germany - effects of opportunistic PSA screening or more?
Rohde V; Weidner W; Katalinic A
Urol Int; 2009; 83(2):134-40. PubMed ID: 19752605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
